Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 16/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 15/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | LOX | P28300 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24660474 | 0.91 | HCRTR2 (0.50) | HCRTR2HCRTR1 | |
| SCHEMBL29324499 | 0.86 | LOX (0.56) | HCRTR2HCRTR1LOXLOXL2 | |
| SCHEMBL4937719 | 0.84 | HDAC6 (0.47) | HCRTR2HCRTR1 | |
| SCHEMBL18069308 | 0.83 | ROCK1 (0.50) | ROCK1HCRTR2HCRTR1LOXLOXL2 | |
| SCHEMBL15649616 | 0.83 | ROCK1 (0.50) | ROCK1HCRTR2HCRTR1LOXLOXL2 | |
| SCHEMBL27303190 | 0.82 | HCRTR2 (0.43) | HCRTR2HCRTR1 | |
| Hydrochloric Acid SCHEMBL18049143 | 0.82 | ROCK1 (0.49) | ROCK1HCRTR2HCRTR1 | |
| Hydrochloric Acid SCHEMBL18049105 | 0.82 | ROCK1 (0.49) | ROCK1HCRTR2HCRTR1 | |
| SCHEMBL450089 | 0.81 | HRH3 (0.57) | HCRTR2HCRTR1 | |
| SCHEMBL12903052 | 0.79 | SLC6A2 (0.54) | HCRTR2HCRTR1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4594318-A1 | AKT1 MODULATORS | Alterome Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11999730-B1 | AKT1 modulators | ALTEROME THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240174667-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024073371-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024073371-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | ROCK1 676/4885HCRTR2 4817/4885HCRTR1 4862/4885 |
| US-20250092040-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | ROCK1 676/4885HCRTR2 4817/4885HCRTR1 4862/4885 |
| US-11999730-B1 | AKT1 modulators | AKT1S1, AKT1, AKT2 | ROCK1 676/4885HCRTR2 4817/4885HCRTR1 4862/4885 |
| US-20240174667-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | ROCK1 676/4885HCRTR2 4817/4885HCRTR1 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.